CoChat

Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation

Li, Yi, Li, Haitao, Liu, Shuai, Pan, Pinhua, Su, Xiaoli, Tan, Hongyi, Wu, Dongdong, Zhang, Lemeng, Song, Chao, Dai, Minhui, Li, Qian, Mao, Zhi, Long, Yuan, Hu, Yongbin, Hu, Chengping · 2018 · Molecular Immunology
Cited by 158

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

HIGHLIGHTSFibroproliferation is present early in LPS‐induced acute lung injury.Pirfenidone ameliorates LPS‐induced pulmonary inflammation and fibrosis.The efficacy of pirfenidone is associated with inhibition of NLRP3 inflammasome activation. ABSTRACT Acute respiratory distress syndrome(ARDS)is a severe clinical disorder characterized by its acute onset, diffuse alveolar damage, intractable hypoxemia, and non‐cardiogenic pulmonary edema. Acute lung injury(ALI) can trigger persistent lung inflammation and fibrosis through activation of the NLRP3 inflammasome and subsequent secretion of mature IL‐1&bgr;, suggesting that the NLRP3 inflammasome is a potential therapeutic target for ALI, for which new therapeutic approaches are needed. Our present study aims to assess whether pirfenidone,with anti‐fibrotic and anti‐inflammatory properties, can improve LPS‐induced inflammation and fibrosis by inhibiting NLRP3 inflammasome activation. Male C57BL/6J mice were intratracheally injected with LPS to induce ALI. Mice were administered pirfenidone by oral gavage throughout the entire experimental course. The mouse macrophage cell line (J774A.1) was incubated with LPS and ATP, with or without PFD pre‐treatment. We demonstrated that PFD remarkably ameliorated LPS‐induced pulmonary inflammation and fibrosis and reduced IL‐1&bgr; and TGF‐&bgr;1 levels in bronchoalveolar lavage fluid(BALF). Pirfenidone substantially reduced NLRP3 and ASC expression and inhibited caspase‐1 activation and IL‐1&bgr; maturation in lung tissues. In vitro, the experiments revealed that PFD significantly suppressed LPS/ATP‐induced production of reactive oxygen species (ROS) and decreased caspase‐1 activation and the level of IL‐1&bgr; in J774A.1 cells. Taken together, the administration of PFD reduced LPS‐induced lung inflammation and fibrosis by blocking NLRP3 inflammasome activation and subsequent IL‐1&bgr; secretion. These findings indicated that PFD can down‐regulate NLRP3 inflammasome activation and that it may offer a promising therapeutic approach for ARDS patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molimm.2018.05.003

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 158

Metadata

Authors
Li, Y., Li, H., Liu, S., Pan, P., Su, X., Tan, H., Wu, D., Zhang, L., Song, C., Dai, M., Li, Q., Mao, Z., Long, Y., Hu, Y., & Hu, C.
Venue
Molecular Immunology
Publisher
Elsevier BV
Published
2018-07
Volume
99
Pages
134-144
ISSN
0161-5890 (ISSN-L)
OpenAlex
W2803657718
Cited by
158
References
13
FWCI
5.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation. https://app.cochat.ai/papers/10.1016/j.molimm.2018.05.003
The paper
Li, Y., Li, H., Liu, S., Pan, P., Su, X., Tan, H., Wu, D., Zhang, L., Song, C., Dai, M., Li, Q., Mao, Z., Long, Y., Hu, Y., & Hu, C. (2018). Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation. Molecular Immunology. https://doi.org/10.1016/j.molimm.2018.05.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.